Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NeuShen Doses First Patient in Trial for Novel Schizophrenia Therapy

publication date: May 8, 2024

Shanghai NeuShen Therapeutics has dosed the first healthy patient in an Australian Phase I trial of its novel selective M4 receptor positive allosteric modulator (M4 PAM), a proposed therapy for schizophrenia. NeuShen believes M4 PAM offers a novel approach to treating schizophrenia, with potential benefits in alleviating symptoms and cognitive impairment. In addition, the candidate may be able to treat psychosis in late-stage Alzheimer's disease or Parkinson's disease. NeuShen developed NS-136 from its proprietary small molecule R&D platform. In preclinical animal tests, the molecule showed efficacy against both positive and negative symptoms of schizophrenia. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here